JOHNSON & JOHNSON - FORM 8-K - EX-99.2 - EXHIBIT 99.2

Attached files

file	filename
EX-99.1 - EXHIBIT 99.1 - JOHNSON & JOHNSON	a2020q1exhibit991.htm
8-K - 8-K - JOHNSON & JOHNSON	a2020q1cover.htm

Exhibit 99.2



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FIRST QUARTER
			Percent Change
	2020	2019	Total			Operations		Currency
Sales to customers by
geographic area

U.S.	$ 10,699	10,129	5.6		%	5.6		—

Europe	4,827	4,609	4.7			7.5		(2.8	)
Western Hemisphere excluding U.S.	1,502	1,503	(0.1	)		8.5		(8.6	)
Asia-Pacific, Africa	3,663	3,780	(3.1	)		(1.9	)	(1.2	)
International	9,992	9,892	1.0			4.0		(3.0	)

Worldwide	$ 20,691	20,021	3.3		%	4.8		(1.5	)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FIRST QUARTER
			Percent Change
	2020	2019	Total			Operations	Currency
Sales to customers by
segment of business

Consumer Health
U.S.	$ 1,740	1,438	21.0		%	21.0	—
International	1,885	1,880	0.3			3.9	(3.6	)
	3,625	3,318	9.2			11.3	(2.1	)

Pharmaceutical
U.S.	6,061	5,582	8.6			8.6	—
International	5,073	4,662	8.8			12.0	(3.2	)
	11,134	10,244	8.7			10.1	(1.4	)

Medical Devices
U.S.	2,898	3,109	(6.8	)		(6.8)	—
International	3,034	3,350	(9.4	)		(6.9)	(2.5	)
	5,932	6,459	(8.2	)		(6.9)	(1.3	)

U.S.	10,699	10,129	5.6			5.6	—
International	9,992	9,892	1.0			4.0	(3.0	)
Worldwide	$ 20,691	20,021	3.3		%	4.8	(1.5	)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	FIRST QUARTER

	2020					2019					Percent
				Percent					Percent		Increase
	Amount			to Sales		Amount			to Sales		(Decrease)
Sales to customers	$ 20,691			100.0		$ 20,021			100.0		3.3
Cost of products sold	7,062			34.1		6,615			33.0		6.8
Gross Profit	13,629			65.9		13,406			67.0		1.7
Selling, marketing and administrative expenses	5,203			25.1		5,219			26.1		(0.3	)
Research and development expense	2,580			12.5		2,858			14.3		(9.7	)
In-process research and development	—			—		890			4.4
Interest (income) expense, net	(42	)		(0.2	)	3			0.0
Other (income) expense, net	(679	)		(3.3	)	(22	)		(0.1	)
Restructuring	58			0.3		36			0.2
Earnings before provision for taxes on income	6,509			31.5		4,422			22.1		47.2
Provision for taxes on income	713			3.5		673			3.4		5.9
Net earnings	5,796			28.0		3,749			18.7		54.6

Net earnings per share (Diluted)	$ 2.17					$ 1.39					56.1

Average shares outstanding (Diluted)	2,671.0					2,698.8

Effective tax rate	11.0		%			15.2		%

Adjusted earnings before provision for taxes and net earnings^{(1) (A)}
Earnings before provision for taxes on income	$ 7,244			35.0		$ 6,867			34.3		5.5
Net earnings	$ 6,154			29.7		$ 5,661			28.3		8.7
Net earnings per share (Diluted)	$ 2.30					$ 2.10					9.5
Effective tax rate	15.0		%			17.6		%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
		First Quarter
	(Dollars in Millions Except Per Share Data)	2020		2019
	Net Earnings, after tax- as reported	$5,796		$3,749

	Pre-tax Adjustments
	Intangible Asset Amortization expense	1,118		1,130
	Litigation expense	120		423
	IPR&D	—		890
	Restructuring related	118		90
	Acquisition and Integration related¹	(962	)	67
	Unrealized (gains)/losses on securities	327		(158	)
	Medical Device Regulation²	14		—
	Other	—		3

	Tax Adjustments
	Tax impact on special item adjustments³	(267	)	(533	)
	Tax legislation and related impacts	(110	)	—
	Adjusted Net Earnings, after tax	$6,154		$5,661
	Average shares outstanding (Diluted)	2,671.0		2,698.8
	Adjusted net earnings per share (Diluted)	$2.30		$2.10
	Operational adjusted net earnings per share (Diluted)	$2.32

	Notes:
	¹Acquisition and integration related costs for the first quarter of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
	²European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
	³The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth ^(A)
FIRST QUARTER 2020 ACTUAL vs. 2019 ACTUAL

Segments
	Consumer Health	Pharmaceutical	Medical Devices	Total
WW As Reported	9.2%	8.7%	(8.2)%	3.3%
U.S.	21.0%	8.6%	(6.8)%	5.6%
International	0.3%	8.8%	(9.4)%	1.0%

WW Currency	(2.1)	(1.4)	(1.3)	(1.5)
U.S.	—	—	—	—
International	(3.6)	(3.2)	(2.5)	(3.0)

WW Operational	11.3%	10.1%	(6.9)%	4.8%
U.S.	21.0%	8.6%	(6.8)%	5.6%
International	3.9%	12.0%	(6.9)%	4.0%

Skin Health / Beauty
Dr. Ci Labo - Japan	(0.4)			(0.1)
U.S.	0.0			0.0
International	(0.7)			(0.1)

General Surgery
Advanced Sterilization Products			2.1	0.8
U.S.			2.7	0.9
International			1.6	0.6

Baby Care
Baby Center	0.3			0.0
U.S.	0.8			0.1
International	0.0			0.0

All Other Acquisitions and Divestitures	(0.2)	0.1	(0.1)	0.0
U.S.	0.0	0.1	(0.2)	0.0
International	(0.3)	0.0	0.1	0.0

WW Adjusted Operational	11.0%	10.2%	(4.8)%	5.6%
U.S.	21.7%	8.7%	(4.3)%	6.7%
International	2.8%	12.0%	(5.3)%	4.5%

Note: Percentages are based on actual, non-rounded figures and may not sum

^(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2020	2019	Reported		Operational⁽¹⁾		Currency
CONSUMER HEALTH SEGMENT^{(2) (3)}

BABY CARE
US	$	92	87	6.7	%	6.7	%	—	%
Intl		269	307	(12.4	)	(8.2	)	(4.2	)
WW		361	394	(8.2	)	(4.9	)	(3.3	)

SKIN HEALTH / BEAUTY ⁽⁴⁾
US		659	588	12.1		12.1		—
Intl		458	502	(8.8	)	(6.5	)	(2.3	)
WW		1,117	1,090	2.5		3.5		(1.0	)

ORAL CARE
US		176	151	16.2		16.2		—
Intl		219	216	1.5		5.3		(3.8	)
WW		395	367	7.6		9.8		(2.2	)

OTC
US		689	507	35.9		35.9		—
Intl		659	580	13.7		17.0		(3.3	)
WW		1,348	1,087	24.1		25.8		(1.7	)

WOMEN'S HEALTH
US		4	3	32.0		32.0		—
Intl		228	222	2.5		8.9		(6.4	)
WW		232	225	2.9		9.2		(6.3	)

WOUND CARE / OTHER
US		119	102	17.0		17.0		—
Intl		52	53	(1.2	)	1.9		(3.1	)
WW		171	155	10.7		11.8		(1.1	)

TOTAL CONSUMER HEALTH
US		1,740	1,438	21.0		21.0		—
Intl		1,885	1,880	0.3		3.9		(3.6	)
WW	$	3,625	3,318	9.2	%	11.3	%	(2.1	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		FIRST QUARTER
				% Change
		2020	2019	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT⁽²⁾

IMMUNOLOGY
US	$	2,410	2,163	11.4	%	11.4	%	—	%
Intl		1,228	1,088	12.8		16.3		(3.5	)
WW		3,638	3,251	11.9		13.1		(1.2	)
REMICADE
US		625	774	(19.3	)	(19.3	)	—
US Exports⁽⁵⁾		110	76	44.3		44.3		—
Intl		256	252	1.5		5.2		(3.7	)
WW		990	1,102	(10.2	)	(9.3	)	(0.9	)
SIMPONI / SIMPONI ARIA
US		272	263	3.4		3.4		—
Intl		258	261	(1.2	)	2.6		(3.8	)
WW		529	524	1.1		3.0		(1.9	)
STELARA
US		1,217	882	37.9		37.9		—
Intl		603	523	15.2		18.3		(3.1	)
WW		1,819	1,405	29.5		30.6		(1.1	)
TREMFYA
US		187	168	11.5		11.5		—
Intl		109	49	*		*		*
WW		296	217	36.4		37.3		(0.9	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		3	3	(6.9	)	(5.6	)	(1.3	)
WW		3	3	(6.9	)	(5.6	)	(1.3	)

INFECTIOUS DISEASES
US		436	357	22.3		22.3		—
Intl		483	489	(1.2	)	2.7		(3.9	)
WW		920	846	8.7		11.0		(2.3	)
EDURANT / rilpivirine
US		12	12	0.6		0.6		—
Intl		212	199	6.4		9.2		(2.8	)
WW		224	211	6.1		8.7		(2.6	)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US		396	315	25.5		25.5		—
Intl		184	208	(11.6	)	(6.4	)	(5.2	)
WW		579	523	10.8		12.8		(2.0	)
OTHER INFECTIOUS DISEASES
US		29	30	(3.4	)	(3.4	)	—
Intl		87	82	6.7		10.2		(3.5	)
WW		116	112	4.0		6.6		(2.6	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		FIRST QUARTER
				% Change
		2020	2019	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (Continued)}

NEUROSCIENCE
US	$	748	723	3.3	%	3.3	%	—	%
Intl		910	905	0.5		3.0		(2.5	)
WW		1,658	1,629	1.8		3.1		(1.3	)
CONCERTA / methylphenidate
US		52	97	(46.1	)	(46.1	)	—
Intl		118	116	1.5		3.6		(2.1	)
WW		171	214	(20.1	)	(19.0	)	(1.1	)
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US		544	483	12.6		12.6		—
Intl		339	307	10.3		13.2		(2.9	)
WW		883	790	11.7		12.9		(1.2	)
RISPERDAL CONSTA
US		76	77	(0.3	)	(0.3	)	—
Intl		94	102	(8.7	)	(5.9	)	(2.8	)
WW		170	179	(5.1	)	(3.5	)	(1.6	)
OTHER NEUROSCIENCE
US		75	66	12.5		12.5		—
Intl		360	379	(5.1	)	(3.1	)	(2.0	)
WW		435	446	(2.5	)	(0.8	)	(1.7	)

ONCOLOGY
US		1,175	962	22.1		22.1		—
Intl		1,839	1,556	18.2		21.7		(3.5	)
WW		3,013	2,518	19.7		21.8		(2.1	)
DARZALEX
US		463	352	31.8		31.8		—
Intl		474	277	70.9		76.8		(5.9	)
WW		937	629	49.0		51.6		(2.6	)
ERLEADA ⁽⁶⁾
US		119	58	*		*		—
Intl		24	3	*		*		*
WW		143	61	*		*		*
IMBRUVICA
US		432	349	23.9		23.9		—
Intl		599	435	37.8		42.3		(4.5	)
WW		1,031	784	31.6		34.1		(2.5	)
VELCADE
US		—	—	—		—		—
Intl		108	263	(59.0	)	(58.2	)	(0.8	)
WW		108	263	(59.0	)	(58.2	)	(0.8	)
ZYTIGA / abiraterone acetate
US		139	185	(25.2	)	(25.2	)	—
Intl		552	494	11.7		14.3		(2.6	)
WW		690	679	1.6		3.5		(1.9	)
OTHER ONCOLOGY ⁽⁶⁾
US		22	18	20.1		20.1		—
Intl		82	84	(2.7	)	0.6		(3.3	)
WW		104	102	1.3		4.1		(2.8	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2020	2019	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (Continued)}

PULMONARY HYPERTENSION
US	$	486	430	13.0	%	13.0	%	—	%
Intl		260	226	14.9		17.8		(2.9	)
WW		745	656	13.7		14.7		(1.0	)
OPSUMIT
US		229	172	33.0		33.0		—
Intl		160	133	20.2		23.3		(3.1	)
WW		389	306	27.4		28.8		(1.4	)
UPTRAVI
US		212	176	20.7		20.7		—
Intl		38	22	70.2		75.0		(4.8	)
WW		250	198	26.2		26.8		(0.6	)
OTHER PULMONARY HYPERTENSION ⁽⁶⁾
US		44	82	(45.9	)	(45.9	)	—
Intl		62	71	(12.4	)	(10.7	)	(1.7	)
WW		106	152	(30.4	)	(29.6	)	(0.8	)


See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2020	2019	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (Continued)}

CARDIOVASCULAR / METABOLISM / OTHER
US	$	806	947	(14.9	)%	(14.9	)%	—	%
Intl		354	398	(11.0	)	(8.7	)	(2.3	)
WW		1,160	1,345	(13.8	)	(13.1	)	(0.7	)
XARELTO
US		527	542	(2.7	)	(2.7	)	—
Intl		—	—	—		—		—
WW		527	542	(2.7	)	(2.7	)	—
INVOKANA / INVOKAMET
US		117	154	(23.6	)	(23.6	)	—
Intl		58	49	18.6		20.9		(2.3	)
WW		175	202	(13.5	)	(12.9	)	(0.6	)
PROCRIT / EPREX
US		76	148	(48.5	)	(48.5	)	—
Intl		79	78	0.4		1.9		(1.5	)
WW		155	226	(31.6	)	(31.0	)	(0.6	)
OTHER
US		85	104	(18.0	)	(18.0	)	—
Intl		217	271	(19.7	)	(17.1	)	(2.6	)
WW		302	374	(19.2	)	(17.4	)	(1.8	)

TOTAL PHARMACEUTICAL
US		6,061	5,582	8.6		8.6		—
Intl		5,073	4,662	8.8		12.0		(3.2	)
WW	$	11,134	10,244	8.7	%	10.1	%	(1.4	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

	FIRST QUARTER
			% Change
	2020	2019	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES SEGMENT ⁽²⁾

INTERVENTIONAL SOLUTIONS
US	365	343	6.6	%	6.6	%	—	%
Intl	362	389	(6.9	)	(5.1	)	(1.8	)
WW	727	732	(0.6	)	0.4		(1.0	)

ORTHOPAEDICS
US	1,250	1,318	(5.2	)	(5.2	)	—
Intl	788	885	(11.0	)	(8.5	)	(2.5	)
WW	2,038	2,204	(7.5	)	(6.5	)	(1.0	)

HIPS
US	206	213	(3.6	)	(3.6	)	—
Intl	132	148	(11.2	)	(8.4	)	(2.8	)
WW	337	361	(6.7	)	(5.6	)	(1.1	)

KNEES
US	214	223	(4.2	)	(4.2	)	—
Intl	130	146	(11.4	)	(8.9	)	(2.5	)
WW	343	369	(7.0	)	(6.1	)	(0.9	)

TRAUMA
US	407	417	(2.3	)	(2.3	)	—
Intl	247	268	(8.0	)	(5.3	)	(2.7	)
WW	654	685	(4.5	)	(3.5	)	(1.0	)

SPINE, SPORTS & OTHER ⁽⁷⁾
US	423	465	(8.9	)	(8.9	)	—
Intl	280	323	(13.3	)	(11.1	)	(2.2	)
WW	703	788	(10.7	)	(9.8	)	(0.9	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)

		FIRST QUARTER
				% Change
		2020	2019	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES SEGMENT ^{(2) (Continued)}

SURGERY
US	$	844	1,001	(15.7	)%	(15.7	)%	—	%
Intl		1,257	1,394	(9.8	)	(6.7	)	(3.1	)
WW		2,100	2,395	(12.3	)	(10.5	)	(1.8	)

ADVANCED
US		381	404	(5.7	)	(5.7	)	—
Intl		567	576	(1.6	)	1.6		(3.2	)
WW		948	980	(3.3	)	(1.4	)	(1.9	)

GENERAL ⁽⁶⁾
US		463	597	(22.5	)	(22.5	)	—
Intl		690	818	(15.7	)	(12.6	)	(3.1	)
WW		1,153	1,414	(18.5	)	(16.8	)	(1.7	)

VISION
US		439	446	(1.6	)	(1.6	)	—
Intl		628	682	(8.0	)	(6.4	)	(1.6	)
WW		1,067	1,129	(5.5	)	(4.5	)	(1.0	)

CONTACT LENSES / OTHER
US		346	321	7.7		7.7		—
Intl		467	502	(7.0	)	(5.4	)	(1.6	)
WW		814	824	(1.3	)	(0.3	)	(1.0	)
SURGICAL
US		93	125	(25.5	)	(25.5	)	—
Intl		160	180	(11.0	)	(9.2	)	(1.8	)
WW		253	305	(16.9	)	(15.9	)	(1.0	)

TOTAL MEDICAL DEVICES
US		2,898	3,109	(6.8	)	(6.8	)	—
Intl		3,034	3,350	(9.4	)	(6.9	)	(2.5	)
WW	$	5,932	6,459	(8.2	)%	(6.9	)%	(1.3	)%

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful
⁽¹⁾ Operational growth excludes the effect of translational currency
⁽²⁾ Unaudited
⁽³⁾ Previously referred to as Consumer
⁽⁴⁾ Previously referred to as Beauty
⁽⁵⁾ Reported as U.S. sales
⁽⁶⁾ Refer to supplemental schedule
⁽⁷⁾ Previously referred to as Spine & Other



Johnson & Johnson
Supplemental Sales Information
(Dollars in Millions)
Prior quarter amounts have been reclassified to
conform to current quarter products disclosure

	2018	2019				2019
	Full Year	Q1	Q2	Q3	Q4	Full Year
PHARMACEUTICAL SEGMENT⁽¹⁾
ERLEADA⁽²⁾
US	124	58	62	74	103	297
Intl	—	3	7	12	13	35
WW	124	61	69	86	116	332

OTHER ONCOLOGY⁽²⁾
US	104	18	16	17	19	70
Intl	362	84	85	83	84	336
WW	466	102	101	100	104	407

PULMONARY HYPERTENSION
OTHER PAH⁽³⁾
US	353	82	61	36	26	205
Intl	342	71	78	61	62	272
WW	695	152	140	96	88	476


MEDICAL DEVICES SEGMENT⁽¹⁾
GENERAL SURGERY⁽⁴⁾
US	2,468	597	530	531	534	2,192
Intl	3,431	818	794	769	834	3,215
WW	5,899	1,414	1,325	1,301	1,366	5,406

Note: Columns and rows within tables may not add due to rounding.

⁽¹⁾ Unaudited
⁽²⁾ ERLEADA was previously included in Other Oncology
⁽³⁾ Other PAH is inclusive of TRACLEER, which was previously disclosed separately
⁽⁴⁾ General Surgery is inclusive of Specialty Surgery, which was previously disclosed separately

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

JOHNSON & JOHNSON - FORM 8-K - EX-99.2 - EXHIBIT 99.2 - April 14, 2020

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports